Urokinase Like Plasminogen Activator Levels in Patients Undergoing Bronchoscopy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00929565
Recruitment Status : Completed
First Posted : June 29, 2009
Last Update Posted : April 9, 2012
Information provided by (Responsible Party):
Gary Kinasewitz, University of Oklahoma

Brief Summary:

Some of the risk factors for bleeding following bronchoscopy is having a malignancy or an immunocompromised state. The etiology of this remains uncertain. The investigators suspect that individuals with malignancy have abnormalities involving certain factors that influence the coagulation pathway.

The investigators plan to measure these factors prior to and after bronchoscopy.

Condition or disease

Detailed Description:
This is a prospective observational study looking at some coagulation factors in individuals with lung cancer. We are looking at BAL and plasma. We would like to see if there is a difference in the levels and if this is the reason behind the higher incidence of hemoptysis in patients with lung cancer.

Study Type : Observational
Actual Enrollment : 10 participants
Observational Model: Case Control
Time Perspective: Prospective
Official Title: Utility of Serum and Bronchoalveolar Fluid Urokinase Like Plasminogen Activator Levels in Defining Patients at Higher Risk of Hemoptysis.
Study Start Date : June 2009
Actual Primary Completion Date : June 2010
Actual Study Completion Date : October 2011

Lung cancer
Comparison between individuals with and without pulmonary malignancy

Secondary Outcome Measures :
  1. Volume of blood loss during the procedure [ Time Frame: 1 day ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients from the VAMC in Oklahoma city

Inclusion Criteria:

  • Any patient scheduled to undergo bronchoscopy

Exclusion Criteria:

  • Patients with evidence of coagulopathy either iatrogenic or the result of disease process - coagulopathy defined as elevated prothrombin time, activated partial thromboplastin time or platelet count less than 100,000
  • Patients not scheduled to undergo bronchoalveolar lavage (BAL)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00929565

United States, Oklahoma
VA Medical Center
Oklahoma City, Oklahoma, United States, 73104
Sponsors and Collaborators
University of Oklahoma
Principal Investigator: Jijo John, MD University of Oklahoma

Responsible Party: Gary Kinasewitz, Principal Investigator, University of Oklahoma Identifier: NCT00929565     History of Changes
Other Study ID Numbers: 14455
First Posted: June 29, 2009    Key Record Dates
Last Update Posted: April 9, 2012
Last Verified: April 2012

Keywords provided by Gary Kinasewitz, University of Oklahoma:

Additional relevant MeSH terms:
Lung Diseases
Respiratory Tract Diseases
Pathologic Processes
Signs and Symptoms, Respiratory
Signs and Symptoms
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action